Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children
Recruiting now · Phase 4
Conditions studied: Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment
In brief
To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate
Key facts
- Study ID
- NCT05520892
- Run by
- Fujian Medical University Union Hospital
- People needed
- 580
- Starts
- 2022-10-06
- Expected to finish
- 2026-08-31
- Last updated by the study team
- 2024-05-16
Who can join
Age: 0 and older, up to 14. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children with newly dignosed ITP — Fuzhou, Fujian, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.